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Abstract
Background: Melanoma is a heterogeneous tumor in which phenotype-switching and CD133 marker have been
associated with metastasis promotion and chemotherapy resistance. CD133 positive (CD133+) subpopulation has
also been suggested as putative cancer stem cell (CSC) of melanoma tumor. Human endogenous retrovirus type K
(HERV-K) has been described to be aberrantly activated during melanoma progression and implicated in the
etiopathogenesis of disease. Earlier, we reported that stress-induced HERV-K activation promotes cell malignant
transformation and reduces the immunogenicity of melanoma cells. Herein, we investigated the correlation
between HERV-K and the CD133+ melanoma cells during microenvironmental modifications.
Methods: TVM-A12 cell line, isolated in our laboratory from a primary human melanoma lesion, and other
commercial melanoma cell lines (G-361, WM-115, WM-266-4 and A375) were grown and maintained in the
standard and stem cell media. RNA interference, Real-time PCR, flow cytometry analysis, self-renewal and
migration/invasion assays were performed to characterize cell behavior and HERV-K expression.
Results: Melanoma cells, exposed to stem cell media, undergo phenotype-switching and expansion of CD133+
melanoma cells, concomitantly promoted by HERV-K activation. Notably, the sorted CD133+ subpopulation
showed stemness features, characterized by higher self-renewal ability, embryonic genes expression, migration
and invasion capacities compared to the parental cell line. RNA interference-mediated downregulation experiments
showed that HERV-K has a decisive role to expand and maintain the CD133+ melanoma subpopulation during
microenvironmental modifications. Similarly, non nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and
nevirapine were effective to restrain the activation of HERV-K in melanoma cells, to antagonize CD133+ subpopulation
expansion and to induce selective high level apoptosis in CD133+ cells.
Conclusions: HERV-K activation promotes melanoma cells phenotype-switching and is strictly required to expand and
maintain the CD133+ melanoma cells with stemness features in response to microenvironmental modifications.
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Background
The origin of intratumoral heterogeneity in melanoma is
not yet clearly defined. However, studies are revealing
that many cancers, including melanoma, are hierarchic-
ally organized and driven by a particular subpopulation
of cancer cells that have stem cells properties, known as
cancer stem cells (CSCs) [1]. CSCs have been defined by
their high self-renewal capacity and tumorigenic poten-
tial leading to tumor initiation, metastasis, therapeutic
resistance and tumor recurrence. Single or multiple
intra- or extra-cellular markers have been used to iden-
tify CSCs in different types of tumors [1, 2]. In melan-
oma, different markers have been employed to
characterize the putative melanoma CSC and, particu-
larly, CD133, CD271, CD146, ALDH, ABCB5, ABCG2,
Nestin and CD117 were considered [3, 4]. Although the
specificity of these markers are still under debate, the
stem cell marker CD133 has been widely used to
characterize and isolate the putative melanoma CSC in
both in vitro and in vivo studies [4, 5]. In fact, CD133
was shown to be expressed in human melanoma biop-
sies but hardly detected in normal skin sections [3, 5].
Furthermore, it was revealed that CD133+ melanoma
cells have an enhanced capability to initiate primary tu-
mors and metastasis in NOD/SCID mice, while show-
ing higher self-renewing and migration capacity and
differentiation potential into mesenchymal lineages in
in vitro studies [4, 6, 7]. Moreover, the CD133 marker
has been associated with promotion of vasculogenic
mimicry and angiogenesis, and was found to inhibit
tumor cell apoptosis by interacting directly with the
vascular endothelial growth factor (VEGF) [8, 9]. Intri-
guingly, recent studies revealed that CD133+ melan-
oma cells are highly resistant to chemotherapy,
indicating that they are also responsible for tumor
recurrence [2, 10]. Likewise, monoclonal antibodies di-
rected against CD133 protein induced a specific dose-
dependent cytotoxic effect in metastatic melanoma
cells, suggesting CD133 as a potential target for im-
munotherapy [11]. Recent evidence also indicated
knocking down CD133 in NRASQ61R/BRAFWT mutant
melanoma renders cells more sensitive to clinically
employed-MEK/BRAF inhibitors [12].
Beyond the notion that melanoma growth and pro-
gression is sustained by stem cell-like cancer cells, it is a
well-evidenced fact that melanoma is driven by a diverse
group of genetic and epigenetic lesions and signaling
pathways that are imposed by change in microenviron-
mental conditions [13, 14]. Nevertheless, in melanoma,
as well in other type of cancers, protein coding gene mu-
tations are no longer considered as sole drivers of the
disease. For these reasons, a growing interest is now
focused on the role of mobile genetic elements in tumor
initiation and progression. These mobile genetic
elements, primarily retroelements, comprise nearly half
of the human genome. Retroelements, unless tightly reg-
ulated, may cause insertional mutagenesis or transcrip-
tional dysregulation that potentially induces cellular
transformation and tumorigenesis [15, 16].
Human endogenous retroviruses (HERVs) belong to
retroelements and are remnants of ancient retrovirus in-
fections that actually constitute about 9% of the human
genome [16]. Most HERVs are defective but there are
few active HERVs that are dynamically expressed and
epigenetically regulated in a stage-dependent manner
during early embryonic development. In somatic tissues,
some members of HERV family remain transcriptionally
active and display tissue-specific expression [16–18]. So
far, HERVs have been implicated in both biological and
pathological processes such as in cancer, diabetes and
neuropsychiatric diseases, but their specific pathophysio-
logical roles are still poorly defined [19–22]. Among
HERV families, HERV-K is the youngest and most active
family that maintains most of the open reading frames
(ORFs) analogous to many active retroviruses [15, 22].
HERV-K viral particles have been identified and charac-
terized at tissue, serum and cell lines level in association
with different types of tumors, including ovarian, breast
and prostate cancer, teratocarcinoma, lymphomas,
leukemia, sarcomas and in more recent years with mel-
anoma [23, 24]. The oncogenic mechanisms of HERV-K
may depend from the expression of gene products po-
tentially carcinogenic or immune escape causative, or
from the regulatory role of their long terminal repeats
(LTRs) sequences for the nearby (proto-) oncogenes or
growth factors [15, 16, 22].
Several studies have shown that HERV-K is aberrantly
activated during melanoma progression, contributes to
cell malignant transformation and promotes immune
escape during metastasis formation [23–28]. HERV-K
Rec and Np9 accessory proteins, described as putative
oncogenes, have been associated with carcinogenesis by
interacting with proteins involved in cellular transform-
ation [29–31]. Likewise, HERV-K env protein may in-
crease the risk of melanoma cancer by disrupting
normal intracellular redox potential resulting in rise of
toxic free radicals [32]. Furthermore, HERV-K proteins
have been shown to suppress the host immune system
[33, 34]. Recent studies also suggested the env protein
of HERV-K might be a key mediator, at least partly, in
the constitutive activation of the RAS-RAF-MEK path-
way, which is aberrantly activated in over 80% of all cu-
taneous melanomas [34–36].
Previously we demonstrated for the first time that
HERV-K activation induced melanoma cell malignant
transformation and reduced the immunogenicity of mel-
anoma cells that favors tumor immune escape [26].
Herein, we show that melanoma cells exposed to stem
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cell media were compelled to undergo phenotype-
switching towards greater malignancy and increment of
stem cell related features concomitant to HERV-K acti-
vation. These phenomena are reversible and promoted
by HERV-K activation. Moreover, this study revealed
that HERV-K activation is strictly required to sustain
CD133+ melanoma cells with stemness features during
microenvironmental modifications.
Methods
Cell lines and culture conditions
In this study the human melanoma primary tumor de-
rived WM-115 cell line, and its metastasis derived coun-
terpart WM-266-4, the malignant human melanoma cell
lines G-361, A375 (all from ATCC, Manassas, VA, USA)
and the human melanoma TVM-A12 cell line, stabilized
in our laboratory, were used [37]. TVM-A12-CD133+
cells were sorted and isolated from TVM-A12 cell line.
All cell lines were cultured as adherent cells in RPMI-
1640 medium supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS), L-glutamine
(2 mM), Penicillin-Streptomycin (100 mg/ml) at 37 °C in
a humidified 5% CO2 atmosphere and serially passaged
twice weekly after detachment with 0.05% trypsin and
0.02% EDTA solution in PBS (all reagents from Sigma-
Aldrich, St Louis, MO, USA). To assess cellular plasticity
and malignant phenotype switching under microenviron-
mental modifications, cells were cultured in the serum-
free stem cells medium X-VIVO™ 15 (Lonza, Verviers,
Belgium) supplemented with Penicillin-Streptomycin
(100 IU/ml).
Flow cytometry analysis
For cytofluorimetric analysis adherent cells were trypsi-
nized, then washed twice in PBS, incubated with 5 μl of
fluorochrome-conjugated antibodies for 30 min at 4 °C
(5 × 105cells/FACS tube), fixed with 1% formaldehyde
solutions for 5 min at 4 °C, centrifuged for 5 min at
1600 rpm and washed once with 1 ml of PBS for 5 min
at 1600 rpm. CD133/2 (293C3) (Miltenyi Biotec,
Bergisch Gladbach, Germany), HLA-I, NGF-R, ICAM-
1, CD20, CXCR4, CD10, c-Kit antibodies (all from BD
Biosciences, Franklin Lakes, NJ, USA) conjugated with
different fluorescent dyes were used; the unconjugated
antibodies Nestin (Novus Biologicals, Minneapolis,
USA) and Melan-A/MART-1 (Santa Cruz Biotechnol-
ogy, Dallas, TX, USA) were used in combination of the
goat-anti-mouse IgG-FITC (BD Biosciences) as second-
ary antibody and used after cell permeabilization. For
apoptosis analysis cells were trypsinized, washed in
PBS, fixed with 70% ethanol for 45 min at 4 °C, washed
in PBS and stained with propidium iodide (50 μg/ml di-
luted in PBS) and RNAase (250 μg/ml), then stored for
at least 3 h at 4 °C before analysis. Flow cytometer
analysis was performed by BD FACScan™ System using
CellQuest Pro software on a minimum of 5000 events
for each sample.
Microscopic and side population analyses
Morphological analysis was carried out by phase-
contrast microscopy, using the Motic AE31 Trinocular
inverted microscope (Motic Asia, Hong Kong).
The differential ability of melanoma cells to efflux
the Hoechst dye [38] was evaluated by Hoechst 33342
extrusion test. In detail, TVM-A12 cells were grown in
X-VIVO medium to induce cellular aggregates. The ob-
tained cellular aggregates were grown on coverslips at
a concentration of 106 cells/ml in X-VIVO medium in
presence of 2% FBS, stained at 37 °C for 90 min with
4 μg/ml Hoechst 33342 (Sigma-Aldrich), and analyzed
without fixing under the ZEISS Axioplan fluorescence
microscope (Oberkochen, Germania) equipped with a
digital camera.
For side population (SP) analysis by flow cytometry,
we adopted the original SP protocol [39] and performed
the analysis as described before [40]. Briefly, TVM-A12
cells cultured in RPMI 10% FBS medium or in X-VIVO
for 72 h were adjusted to 106 cells/ml concentration
and incubated with 5 μg/ml Hoechst 33342 nucleic acid
stain for 90 min at 37 °C. To reduces efflux of the
Hoechst dye and confirm the SP phenotype, Verapamil
(50 μM; Sigma-Aldrich) was added 30 min before
Hoechst stain in control samples. For further SP
characterization, after Hoechst staining, cells were
maintained in ice and immunostained with CD133 or
isotype antibodies (Miltenyi Biotec). Finally, cells were
resuspended in ice-cold staining buffer (PBS + 2%FBS)
for subsequent analysis by flow cytometry using a
FACSCanto II (BD Biosciences).
Flow cytometry sorting
For fluorescence-activated cell sorting, TVM-A12 cells,
cultivated in X-VIVO, were enzymatically dissociated
and stained by incubation with PE-conjugated monoclo-
nal antibody against CD133 and/or PE- isotype mouse
IgG2b at 4 °C for 1 h. After staining, samples were
washed twice with PBS, resuspended at 2 × 106 cells/ml
in PBS and filtered (50 μm, Partech). Live cell sorting
experiments were performed using BD FACSAria II
(Becton Dickinson Immunocytometry Systems) with
130 μm nozzle and sort gates were defined on a dot plot
of CD133 (PE). PE fluorescence of CD133 was deter-
mined by a 488 nm excitation line and detected by 585/
42 nm filters. Sorted cells were collected in PBS
medium. The samples were analyzed using the FACS-
Diva software (Becton Dickinson).
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Sphere formation assay
A total of 500 single viable cells (TVM-A12 and TVM-
A12-CD133+) were seeded into 48-well tissue culture
plates coated with 0.5 mg/ml of poly-2-hydroxyethyl
methacrylate (Poly-HEMA, Sigma) in a 500 μl of
serum-free DMEM/F12 (1:1) (Sigma) basal medium
supplemented with L-glutamine (2 mM), Penicillin-
Streptomycin (100 mg/ml), 20 ng/ml human epidermal
growth factor (EGF) 20 ng/ml, human fibroblast growth
factor-2 (FGF-2) (ProSpec, Rehovot, Israel), and 1:50 B-
27 supplement (Gibco, Life Technologies, Carlsbad,
CA, USA) and cultured at 37 °C in a humidified 5%
CO2 for 10 days to form melanospheres. For serial
passage, these melanospheres were counted using a
manually prepared “quadrant grid” under microscopic
observation, harvested and centrifuged at 1000 rpm for
5 min, trypsinized to dissociate in to single cell,
counted and viable cells reseeded in the Poly-HEMA
coated 48-well plates for subsequent passages.
Migration and invasion assays
For migration assay, cells were maintained in serum-free
RPMI-1640 medium for 18 h, harvested and resus-
pended in the same medium, and seeded into Bio-Coat
cell migration chambers with 8 μm membrane pore sizes
(BD Biosciences) at 1 × 105 cells in 250 μl per chamber.
The chambers were then inserted into the wells of a 24-
well plate containing 750 μl of RPMI-1640 medium with
20% FBS alone or 20% FBS with 40 ng/ml human hepa-
tocytes growth factor (HGF) (ImmunoTools, Friesoythe,
Germany) and incubated at 37 °C with 5% CO2 for 48 h.
After this period, the cells remaining on the upper sur-
face of the membrane were removed with cotton swab
and the cells adhered to the lower surface were fixed
with 70% ethanol for 15 min, stained with Giemsa
(Sigma) for further 15 min, then washed twice with
water. After drying, the membrane was removed with
surgical blade and mounted on glass slides. Pictures
were taken with Olympus BX50 microscope from five
random microscopic fields at 200x magnification, and
cells counted with image analysis software (ImageJ,
NIH). For invasion assay, the same procedure was
followed except for the coating of the migration cham-
bers with 50 μl (0.3 mg/ml) of Matrigel matrix (BD Bio-
sciences) before of the cells seeding.
RNA extraction and real-time PCR
Total cellular RNA was extracted using NucleoSpin
RNA II kit (Machery-Nagel GmbH & Co. KG, Düren,
Germany) following the manufacturer’s instructions. Re-
verse transcription was performed using the ImProm-II™
Reverse Transcription System Kit (Promega, Madison,
USA) following the manufacturer’s instructions. The
Real-time PCR gene-specific primers for HERV-K env,
CD133, and the housekeeping gene beta-glucuronidase
(GUSB) were purchased from Invitrogen Thermo Fisher
Scientific (Waltham MA, USA). The PCR primers for
each specific genes were as follows: env forward, 5′-GCC
ATCCACCAAGAAAGCA-3′; env reverse, 5′-AACTGC
GTCAGCTCTTTAGTTGT-3′ (AF164614); CD133 for-
ward, 5′-TTTCAAGGACTTGCGAACTCTCTT-3′; CD1
33 reverse, 5′-GAACAGGGATGATGTTGGGTCTCA-3′
(NM_001145848.1); Oct4 forward, 5′-TATGCAAAGCA-
GAAACCCTCGTGC-3′; Oct4 reverse, 5′-TTCGGGCAC
TGCAGGAACAAATTC-3′ (NM_002701); Nanog forward,
5′-TCCAGCAGATGCAAGAACTCTCCA-3′; Nanog
reverse, 5′-CACACCATTGCTATTCTTCGGCCA-3′
(NM_024865); GUSB forward, 5′-CAGTTCCCTCCA
GCTTCAATG-3′; GUSB reverse, 5′-ACCCAGCCGA-
CAAAATGC-3′ (NM_000181). Real-time PCR was
performed in CFX96 Real-time System using SsoAd-
vanced™ Universal SYBR Green Supermix (Bio-Rad
Laboratories, Hercules, CA USA) amplification detec-
tion method. Samples were analyzed in duplicate and
for each experiment no template controls (NTC) and
GUSB were used as internal control and to determine
the amplification efficiency, respectively. The threshold
cycle (Ct) comparative method was used to analyze the
relative changes in gene expression of each sample
compared with the reference sample, calculating as fol-
lows:2−[ΔCt(sample) − ΔCt(calibrator)] = 2−ΔΔCt, where ΔCt
(sample) = [Ct (HERV-Kenv) – Ct (GUSB)], and ΔCt
(calibrator) was the mean of ΔCt of TVM-A12 cells
maintained in RPMI 10%FBS.
RNA interference
HERV-K (AF164614) expression was down-regulated by
infecting TVM-A12 cells with a retroviral vector as pre-
viously described [26, 27]. Briefly, Phoenix packaging
cells were transfected with 9 μg of construct DNA using
lipofectamine (Gibco-BRL, 18324–012). 48 h later, cell
culture media were collected and filtered through
0.45 μm Millipore filter and used to infect TVM-A12
cells in the presence of 4 μg/ml polybrene (Sigma) for
12 h, after which the medium was changed. Infected
cells were selected on 0.5 μg/ml puromycin (Sigma) for
6 days. After selection, the cells were grown in RPMI-
1640 medium supplemented with 10% FBS and main-
tained under antibiotic selection (0.2 μg/ml).
Reverse transcriptase inhibitors treatments
TVM-A12 and TVM-A12-CD133 cells were cultured for
24 h in RPMI-1640 medium with 10% FBS at 37 °C and
5% CO2 to ensure cells form a monolayer before starting
treatment. Then, cells were cultivated in RPMI-1640
with 10% FBS, or in serum-free stem cell media (X-
VIVO™ 15) to induce the grape-like cellular aggregates
formation. The non-nucleoside reverse transcriptase
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(RT) inhibitors (NNRTIs) nevirapine (NVP) or efavirenz
(EFV) were added to the cultures at 350 μM and 15 μM
respectively. Dimethyl sulfoxide (DMSO) was used as di-
luent for the drugs and was referred as vehicle in control
condition. After 72 h of treatment cells were detached
(trypsin used only for adherent cells) and back cultured
with the same fresh media for the next 24 h and
retreated with NVP or EFV at half concentration of ini-
tial used. Finally cells from each condition were col-
lected and processed for Real-time PCR and flow
cytometry analysis.
Statistical analysis
Data analysis was performed using the SPSS statistical
software system (version 17). Comparison of means was
carried out using Bonferroni post-hoc multiple compari-
son Anova test. Statistical probabilities were expressed
as p ≤0.050 (*) or p < 0.001 (**).
Results
TVM-A12 human melanoma cells led to phenotype
switching and expansion of the CD133+ melanoma
subpopulation when cultured in stem cell medium
In order to investigate the phenotype modifications of
melanoma cells undergoing change of the microenviron-
ment, the TVM-A12 melanoma cell line was cultured in
a serum free stem cell medium (X-VIVO-15) and mor-
phological features, cellular markers and antigens
expression were characterized. As shown in Fig. 1a
TVM-A12 cells, in the standard condition (RPMI +
10% FBS), displayed adherent phenotype and heteroge-
neous morphology, including small ovoid, spindle
polygonal and large dendritic forms. However, when
cultured in the X-VIVO medium, TVM-A12 cells
showed a reduced proliferative potential, while the
morphology shifted towards the formation of
anchorage-independent grape-like cellular aggregates,
characterized also by a dark colour due to melanin in-
crease. In response to a gradual increment of serum
(FBS) to X-VIVO medium, up to 10%, cells progres-
sively reverted to an adherent phenotype within 72 h,
with lower melanin content and morphology similar to
the original one. These results demonstrate that TVM-
A12 cells have an inherent characteristic of adaptive
plasticity in response to the variations of the culture
condition.
The phenotypic switching of TVM-A12 cells was
characterized by flow cytometry analysis, using specific
antibodies against selected cell surface markers of mel-
anoma malignancy. The analysis was performed both
on the adherent TVM-A12 cells, maintained in stand-
ard RPMI medium containing 10% FBS, and on the
non-adherent grape-like cellular aggregates, induced by
the X-VIVO medium (Fig. 1b, c). The morphological
transition of TVM-A12 melanoma cells from adherent
to suspended cellular aggregates, observed in X-VIVO
medium, was accompanied by significant down-
regulation of cell surface molecules such as HLA-I,
Melan-A/MART-1 antigen, ICAM-1 and c-Kit, by
maintenance or increase of tumour metastasis-
associated markers such CXCR4 and CD10, and the in-
crease of putative markers of CSCs such as CD133,
Nestin, and NGF-R. For CD20 marker, which has been
previously described as CSC marker in melanoma [3],
not significant modification was determined. Moreover,
flow cytometry analysis revealed that the addition of
serum up to 10% to X-VIVO medium, other than re-
establish the original morphology as already described
in Fig. 1a, was also accompanied by the recovery of ex-
pression levels of the cellular markers of TVM-A12
grown in RPMI containing 10% FBS (data not shown).
Interestingly, the Hoechst 33342 extrusion test per-
formed in living cells revealed also the presence in
TVM-A12 of cells that exhibited similar property of
CSCs, such enriched chemoresistance and tumorigenesis
[3, 40]. X-VIVO medium with 2% of serum concentra-
tion was selected as condition in which non-adherent
grape-like cellular aggregates and attached adherent cells
were simultaneously present (Fig. 1d). The grapes in
suspension showed (see arrows in Fig. 1d) different
ability to efflux Hoechst. To better characterize this
phenomenon, SP analysis was performed by flow cy-
tometry (Fig. 1e). Using this method, the presence of a
side population in TVM-A12 cell line was identified.
Indeed, when the TVM-A12 cells cultured in standard
RPMI medium were preincubated with verapamil be-
fore adding Hoechst 33342 dye, the percentage of SP
cells significantly reduced, which is consistent with re-
ports that verapamil blocks Hoechst efflux. Interest-
ingly, part of these SP cells expressed CD133 marker,
suggesting CD133 as one of the surface markers that
potentially can be used to distinguish the population
with stemness features in melanoma cells. Furthermore,
in TVM-A12 cells cultured in X-VIVO, SP analysis
identified a side population with a relative expression
of the CD133 marker showing drug resistance features.
In light of our previous report that demonstrated the
contribution of HERV-K to melanoma malignancy [26],
we further investigated the activation of HERV-K in
TVM-A12 melanoma cells during the expansion of
CD133+ subpopulation in X-VIVO medium. To this
end, using Real-time PCR, we evaluated the expression
of HERV-K type II env gene (referred then in the text
as HERV-K) in TVM-A12 cells upon their morpho-
logical transition from adherent to non-adherent
grape-like cellular aggregates. Figure 1f shows a tran-
scriptional activation of HERV-K concomitant to the
phenotype-switching caused by exposure to X-VIVO
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Fig. 1 (See legend on next page.)
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medium. Interestingly, HERV-K transcriptional activity
back to previous observed levels together with the re-
acquisition of the adherent phenotype upon re-
exposure to RPMI with 10% FBS.
The increased expression of markers related to both
stem cells and malignancy during in X-VIVO culture
and the SP analysis, suggested the expansion and main-
tenance of a stem cell-like CD133+ subpopulation. To
further study this stem cell-like subpopulation, CD133+
cells were sorted through a flow cytometry based tech-
nique from the TVM-A12 (Fig. 2a). After sorting, cells
were cloned by limiting dilution technique in standard
RPMI medium with 10% FBS and stabilized as adherent
cell lines with high CD133 expression level. In close ana-
logy with the parental TVM-A12 cells, the exposure of
TVM-A12-CD133+ cells to X-VIVO medium triggered
the morphological transition from adherent to non-
adherent phenotype (Fig. 2b) and maintained high levels
of CD133 expression as shown by flow cytometry
(Fig. 2c). Of note, the sorted TVM-A12-CD133+ cells
can be maintained in the standard RPMI medium for a
long time, showing gradually a reduction of CD133 ex-
pression. However, in the present study, we used only
short cultured sorted cells analysed by FACS for CD133
expression immediately before the experiments, for the
confirmation of the relative percentage of expression (in
all the experiment >70%).
Taken together, these results demonstrated that TVM-
A12 human melanoma cells have a change-prone pheno-
type responding to microenvironment modification,
characterized by the expansion of a CD133+ melanoma
subpopulation, enhanced expression of HERV-K and of
markers related to immune evasion and metastasis
formation.
TVM-A12-CD133+ melanoma cells displayed enhanced
self-renewing potential, migration and invasion capacity
To verify if the TVM-A12 and TVM-A12-CD133+ cell
lines exhibit some feature typical of cancer stem cells,
we adopted sphere-forming assay, a technique widely
used to characterize the CSCs self-renewing properties.
Figure 3a shows that both cell lines were able to gener-
ate melanoma spheroids (melanospheres). Throughout
the subsequent passages, the melanospheres forming ef-
ficiency of TVM-A12-CD133+ cells was significantly
higher than the parental TVM-A12 cells (second passage
p = 0.004, third passage p = 0.012), and only TVM-A12-
CD133+cells were able to achieve a highly significant in-
crement in the number of melanospheres between the
first and third passage (p < 0.001). Together, these results
show that TVM-A12-CD133+ cells have a greater self-
renewing potential than the parental TVM-A12 cells.
We then compared the migratory/invasive capacity of
TVM-A12 and TVM-A12-CD133+ cells using a trans-
well migration chamber in which cells were cultured for
48 h in RPMI with 20% FBS in the presence or not of
40 ng/ml hepatocyte growth factor (HGF). No significant
difference in migration was found between the two cell
lines cultured in RPMI medium with 20% FBS. However,
the migration potential of both cell lines were strongly
enhanced in the presence of 40 ng/ml HGF compared to
the 20% FBS alone (p < 0.001), underlining the need of
factors, typically present in tumour microenvironment
known to promote migration of melanoma cells. Note-
worthy, in the presence of HGF, the TVM-A12-CD133+
cells displayed a significantly higher cell migration po-
tential than the parental TVM-A12 cells cultured in the
same condition (p < 0.001) (Fig. 3b). Likewise, in a
Matrigel coated inserts of transwell migration chambers,
resembling the in vivo extracellular complex microenvir-
onment, the presence of HGF stimulated invasion in
both cell lines (p < 0.001), with the TVM-A12-CD133+
cells showing a significantly higher capacity to invade
through the Matrigel compared to TVM-A12 cells (p <
0.001) (Fig. 3c).
Likewise, Real-time analysis of the core pluripotent
regulatory transcription factors Oct4 and Nanog expres-
sion, which are well known to contribute the stemness
and aggressive features of CSCs, revelead that both the
parental TVM-A12 cell line and the sorted TVM-A12-
(See figure on previous page.)
Fig. 1 TVM-A12 cells exhibit adaptive plasticity, phenotype switching and concomitant up-regulation of HERV-K expression upon microenvironmental
modifications. a Phase contrast microscopy of TVM-A12 grown in RPMI-1640 complete medium, in stem cell medium (X-VIVO) or upon the addition of
increasing percentage of serum (up to 10% of FBS), where cells reverse their original phenotype within 72 h; original magnification: left panels, 10x;
right panels, 20x. b Flow cytometry analysis after extracellular staining of TVM-A12 melanoma cells undergoing from adherent growth, in RPMI-1640
complete medium, to grape-like cellular aggregates in X-VIVO medium. c Flow cytometry analysis after intracellular staining of TVM-A12 melanoma
cells undergoing from adherent growth, in RPMI-1640 complete medium, to grape-like cellular aggregates in X-VIVO medium. d Fluorescence
microscopic analysis of Hoechst 33342 staining on living TVM-A12 cells growing in low serum X-VIVO medium (2% FBS); arrows point to
putative cancer stem cells exhibiting low or negative Hoechst positivity in the nuclei. Original magnification: 40x. e Shows identification and
characterization of the SP cells from TVM-A12 melanoma cells cultured for 72 h in RPMI-1640 complete medium or X-VIVO using Hoechst
33342 nucleic acid stain by FACS analysis. The FACS dot-plots displays the SP cells co-stained with CD133 marker preincubated with verapamil
(left panel) and in the absence of verapamil (middle panel). Likewise, the FACS histograms plots (right panel) displays the percentage of CD133+ cells
and the median of the relative fluorescence within the total SP cells in the absence of verapamil. f Relative mRNA expression of HERV-K env gene in
TVM-A12 melanoma cells upon modification of culture conditions (** p < 0.001). Data represent the results of three independent experiments
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CD133+ cells express these embryonic genes (Fig. 3d).
Interestingly, the exposure to X-VIVO induced a sta-
tistically significant modulation of Oct4 in TVM-A12-
CD133+ cells (p < 0.001). These results add further
evidence of stemness features in the sorted CD133+
melanoma cells. These results confirm that TVM-
A12-CD133+ cells have the inherent nature of stem
cells properties that demarcates the defining feaures of
CSCs.
On the whole, these results indicated that the parental
TVM-A12 melanoma cells contain a CD133+ subpopulation
endowed with features typical of CSCs such as high
self-renewal and migratory/invasive capacity and em-
bryonic genes expression.
Concomitant CD133+ cells expansion and HERV-K
activation in different melanoma cell lines
We then assessed if different melanoma cell lines, other
than TVM-A12, were able to undergo morphological
modification and express CD133 marker at higher level
when cultivated in X-VIVO medium. Similar to TVM-
A12, all the four melanoma cell lines (G-361, WM-155,
Fig. 2 Cloned TVM-A12-CD133+ cells show adaptive plasticity similar to the parental TVM-A12 melanoma cells. a Sorting of CD133+ subpopulation
from TVM-A12 cells by flow cytometry-based side population technique. b Phase contrast microscopy image of adherent cells (left panel) and
grape-like cellular aggregates (right panel) of TVM-A12-CD133+ in RPMI-1640 and X-VIVO medium, respectively: magnification 10x. c Flow
cytometry analysis of CD133 expression of adherent (left panel) and non-adherent (right panel) TVM-A12-CD133+ cells. Data represent the
results of three independent experiments
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Fig. 3 (See legend on next page.)
Argaw-Denboba et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:20 Page 9 of 17
WM-266-4 and A375) were able to undergo a morpho-
logical transition upon exposure to X-VIVO medium,
but showed variable tendency to maintain and expand
CD133+ subpopulation (Fig. 4a). Indeed, similar
to TVM-A12, also G-361 and WM-115 cell lines
showed an increased expression of CD133 when culti-
vated in X-VIVO (quadrant 1 + quadrant 2 of the dot-
plots). On the other hand, WM-266-4 and especially
A375 failed to increase CD133 marker in this culture
condition. The different increased of CD133 expression
among each cell lines was confirmed by Real time analysis
(Fig. 4b). Intriguingly, this result is associated with the
relative expression level of HERV-K (Fig. 1c). Indeed, the
cell lines that failed to expand CD133 subpopulation in X-
VIVO were those with lower or not significant HERV-K
activation during exposure to microenvironment
alterations.
These results highlight an association between the
HERV-K activation under microenvironment alterations
and the expansion of a CD133+ subpopulation with
stemness features.
Downregulation of HERV-K expression abolished the
expansion of CD133+ melanoma subpopulation
We then investigated the role of HERV-K on cell plasti-
city and the maintenance of CD133+ cells in stem cell
medium by downregulating HERV-K expression via
RNA interference. TVM-A12 cells, infected with a
retroviral vector expressing HERV-K-interfering
shRNAs (pS-H-Ki construct) or with non-interfering
retroviral vector alone (pS-puro construct), when cul-
tured in the standard RPMI medium with 10% FBS,
both exhibited an adherent phenotype. When cultured
in X-VIVO medium, the pS-puro-infected cells
switched towards the non-adherent aggregates forma-
tion, as the non-infected TVM-A12 cells, while pS-H-
Ki-interfered cells were abnormal in X-VIVO showing
less regular cellular aggregates morphology and reduc-
tion of cell growth compared to the TVM-A12pS-puro
(Fig. 5a, b). Real-time PCR demonstrated that both
TVM-A12 and TVM-A12pS-puro cell lines expressed
higher levels of HERV-K env gene when cultivated in
X-VIVO medium, compared to standard culture con-
dition in RPMI medium with 10% FBS (p < 0.001). In
contrast, as a result of HERV-K interference, in TVM-
A12pS-H-Ki cells the expression of HERV-K env gene
was strongly inhibited in both culture conditions
(Fig. 5c).
In light of these results, we further investigated if the
maintenance of the CD133+ cells in X-VIVO medium
was dependent from the expression of HERV-K. Real-
time PCR showed that in TVM-A12pS-puro, cultured
in X-VIVO, the expression of CD133 mRNA was acti-
vated (p < 0.001), while in TVM-A12pS-H-Ki interfered
cells the expression of CD133 was strongly inhibited
(Fig. 5d). Flow cytometry analysis, also confirmed
HERV-K dependency of the CD133+ subpopulation in
X-VIVO. Indeed, the cell lines (TVM-A12, TVM-
A12pS-puro or TVM-A12pS-H-Ki) cultured in stand-
ard RPMI medium with 10% FBS retained a similar
percentage of CD133+ cells. However, when these cells
were cultured in X-VIVO medium, both TVM-A12 and
TVM-A12pS-puro cell lines were able to expand and
maintain the subpopulation of CD133+ cells, while in
the TVM-A12pS-H-Ki cell line the expansion was sig-
nificantly abolished reaching a relative percentage of
cell expressing CD133+ lower than in standard condi-
tion (Fig. 5e).
Throughout these results indicate that the downregu-
lation of HERV-K prevents both the morphological
transition of TVM-A12 cells towards a more malignant
phenotype and the expansion of the CD133+ cells in-
duced by X-VIVO medium.
High susceptibility of TVM-A12-CD133+ melanoma cells
to non-nucleoside reverse transcriptase inhibitors
treatment
We have previously described that the non-nucleoside
reverse transcriptase inhibitors (NNRTIs) Nevirapine
and Efavirenz, currently used in the treatment of HIV
patients, reduce proliferation and induce cell differenti-
ation in TVM-A12 cells [41]. Thus, we wanted to verify
(See figure on previous page.)
Fig. 3 TVM-A12-CD133+ cells are endowed with CSCs features more than the parental TVM-A12 cells. a TVM-A12-CD133+ melanoma cells show
higher self-renewing potential than TVM-A12 cells. Top panels represent the microscopy pictures of melanospheres from TVM-A12 cells (left) and
TVM-A12-CD133+ cells (right); magnification 10x. Bar graph displays the self-renewing efficiency difference between TVM-A12 and TVM-A12-CD133+
cells in 2nd passage (p = 0.004) and 3rd passage (p = 0.012) and between 1st and 3rd passage of TVM-A12-CD133+ cells (** p < 0.001). b TVM-A12-
CD133+ cells display higher migratory capacity than TVM-A12 cells. Top panels represent the microscopy pictures of TVM-A12 and TVM-A12-CD133+
migrated through the transwell insert: magnification 20x. Bar graph shows the migration capacity of TVM-A12 and TVM-A12-CD133+ cell lines in the
presence or not of 40 ng/ml HGF (** p < 0.001). c TVM-A12-CD133+ cells display higher invasive capacity than TVM-A12 cells. Top panels represent the
microscopy pictures of TVM-A12 and TVM-A12-CD133+ invasive cells through Matrigel coated transwell inserts: magnification 20x. Bar graph shows the
invasive capacity difference between TVM-A12 and TVM-A12-CD133+ cell lines in the presence or not of 40 ng/ml HGF (** p < 0.001). ImageJ software
was used to count total migrated and invasive cells. p-values (* p≤ 0.050; ** p < 0.001). d Expression of the core stem cells transcriptional factor Oct4
(left panel) and Nanog (right panel). Data represent the results of three independent experiments
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the effect of NNRTIs treatment on the TVM-A12-
CD133+ subpopulation. The data obtained showed that
in X-VIVO medium, where HERV-K is highly activated
and CD133+ cells expanded, the percentage of CD133
expressing cells within TVM-A12 cell line were signifi-
cantly reduced from 28.7% in the control, to 10.8 and
10.7% upon treatment with nevirapine and efavirenz,
respectively (Fig. 6a). Under the same conditions, the
percentage of CD133+ expressing cells in TVM-A12-
CD133+ cell line was also significantly reduced from
72.5% in control to 23.1 and 39.5%, after treatment with
nevirapine and efavirenz, respectively (Fig. 6b). More-
over, in X-VIVO medium apoptosis was moderately
induced in TVM-A12 cell line treated with nevirapine
(35.3%) and efavirenz (26.5%), as compared to the 11.3%
in control sample (Fig. 6c), while a significantly higher
level of apoptosis was induced in TVM-A12-CD133+
cell line by nevirapine (70.2%) and efavirenz (79.5%),
compared to the 9.6% in control sample (Fig. 6d). The
analysis by Real-time PCR, showed that the effect of the
inhibitors efficiently prevented the activation of HERV-K
in TVM-A12 cells and TVM-A12-CD133+ cell lines (p
< 0.001) (Fig. 6e). Interestingly, in both the cell lines, the
down-regulation of HERV-K was accompanied by a par-
allel down-regulation of CD133 expression (p < 0.001)
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Fig. 4 Different melanoma cell lines increase CD133 marker upon activation of HERV-K. a Morphological transition (left panel) and CD133
expression by flow cytometry (right panel) of human melanoma cell lines (G-361, WM-155, WM-266-4 and A375) upon exposure to X-VIVO
medium: magnification 10x. Relative mRNA expression of CD133 (b) and HERV-K (c) in different melanoma cell lines upon modification of
culture conditions. p-values (* p ≤ 0.050; ** p < 0.001). Data represent the results of three independent experiments






















































































































































































































































































Fig. 5 (See legend on next page.)
Argaw-Denboba et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:20 Page 12 of 17
inhibition of endogenous reverse transcriptase by the
NNRTIs prevents the activation of HERV-K and is con-
comitantly accompanied by the CD133 down-regulation
and the inability to expand and maintain the CD133+
cells.
Discussion
In different types of tumors CSCs have been shown to
possess an inherent characteristic of cellular plasticity to
resist and survive in harsh microenvironment conditions,
encountered during tumor progression [2]. In melanoma,
CSCs plasticity has been related to intratumoral hetero-
geneity, metastasis formation, resistance to chemotherapy
and tumor recurrence [7].
In the present study TVM-A12 human melanoma cell
line, originated from a primary lesion, showed peculiar
plasticity features upon the modification of microenvir-
onment by cultivation in a stem cell medium, switching
from an adherent phenotype towards an anchorage-
independent grape-like cellular aggregates formation.
This morphological transition was accompanied by the
acquisition of more aggressive and invasive characteris-
tics such as significantly reduced expression of cell sur-
face markers HLA-I, MelanA/MART-1 and ICAM-1, all
involved in the host immune response [42–44]. This is
in agreement with our previous paper, in which we
described the contribution of HERV-K in reducing the
immunogenicity of melanoma cells [26] and therefore
favoring the evasion of the tumour from the host
immune responses [1]. In addition, herein increased ex-
pression of stem cells and metastasis related markers
CD133, nestin, CXCR4, and NGF-R along with contin-
ued high-level of CD10 expression were observed,
which usually delineates progression to advanced stage
of melanoma and metastatic tumour formation [4, 45].
Moreover, the survival of TVM-A12 cells in non-
adherent condition implied these cells may have devel-
oped a mechanism to resist and thereby survive after
detachment. Likewise, metastatic cancer cells are able
to survive after detachment from their primary site by
developing resistance to a specialized form of cell death
called anoikis [46, 47].
It was described that HERV-K expression may support
cancer cells to go through fast gene plasticity to adopt
new microenviromental changes [16, 48]. Hence, the
phenotype-switching of TVM-A12 cells, occurring in the
stem cell medium, and the concomitant HERV-K activa-
tion, both reversible after serum addition, highlight that
TVM-A12 cells harbor a high capacity to adapt to the
microenvironment modifications, while maintaining an
inherent ductility to reestablish the original features.
Intriguingly, silencing HERV-K in TVM-A12 cells atten-
uated their plasticity towards invasive malignant pheno-
type, which seems to affirm that in melanoma cells the
aberrant activation of HERV-K is associated with the
process of invasive phenotype-switching, occurring in
response to microenvironmental modification. This find-
ing corroborate previous reports demonstrating melan-
oma cells undergo the process of phenotype-switching
to promote metastatic state while maintaining the stem
cell-like identity [14, 49].
In this study the expansion of the CD133+ subpopula-
tion and the concomitant up-regulation of HERV-K were
observed during the morphological transition of TVM-
A12 cells towards the non-adherent malignant pheno-
type. Interestingly, we found that these phenomena are
not limited to TVM-A12 melanoma cell line, rather
they are seemingly common traits shown with different
extent by other type of commercially available melan-
oma cell lines. Indeed, all the cell lines tested showed
various basal expressions of CD133 marker and apti-
tude to expand this subpopulation, concomitantly with
HERV-K activation, when maintained in stem cell
medium. Remarkably, blocking of HERV-K expression
through siRNA significantly abolished the expansion
and maintenance of CD133+ subpopulation within
TVM-A12 cells in the stem cell medium. It is also well
documented that the main defining characteristics of
putative CSCs are self-renewing and metastatic poten-
tial [50] as well as the expression of pluripotent stem
cells transcription factors, such as Nanog, Oct4, and
Sox2 [51]. From this perspective, this study showed that
the TVM-A12-CD133+ cells, which are dependent on
HERV-K activation, are endowed with the defining
characteristics of CSCs as evidenced by their enhanced
self-renewal ability, higher migratory and invasive cap-
acities and expression of the stem cell markers Oct4
and Nanog. This study also showed CD133+ subpopu-
lation is partly present in the Hoechst dye-effluxing SP
cells, which possess many CSCs properties [40]. These
findings seems to indicate that HERV-K is also involved
in the stemness genomic networks of the CSCs model
(See figure on previous page.)
Fig. 5 Downregulating of HERV-K expression by RNAi abolishes the expansion of CD133+ subpopulation. a Phase contrast microscopy image of
adherent cells in RPMI-1640 medium (upper panels) and grape-like cellular aggregates in X-VIVO medium (lower panels) from TVM-A12pS-puro
(non-interfered) and TVM-A12pS-H-Ki (interfered) cells: magnification 20x. b Cell counts. Relative mRNA expression of HERV-K env gene (c) and
CD133 (d) in TVM-A12pS-puro and TVM-A12pS-H-Ki cells upon modification of culture conditions. e Flow cytometry analysis of CD133 expression
shows HERV-K RNAi abolished the expansion and maintenance of CD133+ subpopulation in X-VIVO medium. Data represent the results of three
independent experiments
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Fig. 6 (See legend on next page.)
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in melanoma tumor. In support to this hypothesis,
compelling evidences suggest that expression of HERVs
have a direct participatory role for the maintenance of
human embryonic stem cells (hESCs) and induced
pluripotent stem cells (iPSCs), and, their activation or
re-activation have been evinced as a marker of pluripo-
tency [16, 31]. Likewise, HERV-K has been associated
with cellular transformation and carcinogenesis [16, 23,
25]. Of note, very recently has been demonstrated the
essential role of HERV-K env protein activation for
tumorigenesis and metastasis of breast cancer cells
[52]. In this regard, our study presents the first evi-
dence that demonstrate the fundamental role of
HERV-K in the expansion and maintenance of CSCs in
melanoma tumor during phenotype switching under
microenvironment modifications.
It has been shown that microenvironmental stress
conditions influence the expression of HERVs in cancer
cells through epigenetic modification, most likely
through DNA hypomethylation of relevant retroviral
genes [23]. Moreover, it was reported that DNA hypo-
methylation is accounted as an important determining
factor of CD133 expression in ovarian and glioma cancer
cells [53, 54]. Global DNA hypomethylation is a hall-
mark of many cancers [55] and HERV-K (HML-2) hypo-
methylation in particular has been reported in
melanoma cell lines [56]. Hence, the aberrant activation
of HERV-K in melanoma cells could depend on the epi-
genetic modification induced by change in tumor micro-
environment that affects the DNA methylation state.
Taken together, this study revealed that the expansion of
CD133+ melanoma cells with stemness features are
dependent on HERV-K activation during microenviron-
ment modifications, likely mediated by stress condition.
We previously reported that inhibition of retroelements-
encoded RT by NNRTIs or by RNA interference, resulted
in anti-proliferative, pro-differentiating effects in melanoma
cells and reduction of melanoma tumor growth in mice
models [27, 41, 57]. Interestingly, here we found that
efavirenz and nevirapine were able to halt the expan-
sion and maintenance of CD133+ melanoma cells indu-
cing high levels of apoptosis and were effective to
restrain the activation of HERV-K during microenvi-
ronmental modification. Therefore, the high sensitivity
of TVM-A12-CD133+ cells to NNRTIs suggests a spe-
cific requirement of HERV-K expression to sustain this
subpopulation in melanoma cells during microenviron-
mental modifications. This result confirms our previous
findings that retroelements are key players in melan-
oma tumor progression [41, 57–59], demonstrating for
the first time the specific role of HERV-K in the gener-
ation and survival of CD133+ melanoma CSCs. These
findings open new perspectives for targeting the puta-
tive CSCs that express high-level of HERV-K and for
developing new possible therapeutic strategies based on
tumor cells differentiation.
Conclusions
Taken overall, findings from this study demonstrated the
involvement of HERV-K in the plasticity of human mel-
anoma cells undergoing change of microenvironment,
with a peculiar role on the CD133+ subpopulation
endowed with CSC features. In light of this, and based
on previous evidences reported by our group and others,
it possible to address HERV-K as one of the important
actors in the dynamics of melanoma development. Par-
ticularly, we demonstrated that HERV-K accompany
phenotype switching and is strictly required to sustain
the more malignant CD133+ subpopulation of cancer
cells with stemness features.
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